Synlogic Names Metera’s David Hava as Chief Scientific Officer

Xconomy Boston — 

David Hava has joined Synlogic (NASDAQ: SYBX) as chief scientific officer, the same position he held most recently at Metera Pharmaceuticals. He also previously served as chief scientific officer of Pulmatrix (NASDAQ: PULM). Cambridge, MA-based Synlogic is engineering bacteria to serve as “living medicines.” The biotech’s lead program, SYB1618, is in mid-stage development as a treatment for the rare metabolic disorder phenylketonuria.